head JofIMAB
Journal of IMAB - Annual Proceeding (Scientific Papers)
Publisher: Peytchinski Publishing Ltd.
ISSN: 1312-773X (Online)
Issue: 2022, vol. 28, issue4
Subject Area: Public Health
DOI: 10.5272/jimab.2022284.4688
Published online: 18 November 2022

Original article
J of IMAB. 2022 Oct-Dec;28(4):4688-4690
Ivaylo Pakov1, 2ORCID logo Corresponding Autoremail, Elena Birindzhieva2, Ivva Philipova3ORCID logo, Kalina Terzieva1ORCID logo, Galya Gancheva1ORCID logo,
1) Department of Infectious Diseases, Epidemiology, Parasitology and Tropical Medicine, Faculty of Public Health, Medical University-Pleven, Bulgaria.
2) Checkpoint Sofia – Centre for Sexual Health, Sofia, Bulgaria.
3) National Center of Infectious and Parasitic Diseases, Sofia, Bulgaria.

HIV is a major global public health problem.The increased access to effective prevention, diagnosis and treatment transformed HIV-infection intoa manageable chronic health condition.Our purpose was to assess the effectiveness of oral pre-exposure prophylaxis (PrEP) of HIV-infection.
Material and Methods: CheckPoint Sofia (former Sexual Health Centre – Sofia) is a medical center for consultations, prevention, diagnosis and treatment of sexually transmitted infections (STI’s) and HIV/AIDS. A retrospective study was conducted on 410 consulted males (HIV-seronegative) (October 2020 to August 2022).
Results: The mean age was 32±7.6 years (18-57 years) with prevalent ages <30 and 30-40 years (42% and 47%, respectively); Bulgarian citizens 90%, MSM (97%). The clients’ profile revealed active sporting (38%), past STI’s (26%), vaccinated for HBV (54%). No one of the subjects had chronic kidney disease and mandatory investigations of renal functions at starting of PrEP revealed mean levels of urea and creatinine 4.9±1.42 mmol/L and 78±18.2 µmol/L, respectively. On demand regimen (2+1+1 tablets) of PrEP was preferred at 91% and 15% switched to everyday receiving before an increased risk. After starting of PrEP, 55% of the subjects were tested voluntary and no one was positive for HIV, HBV, and HCV. The once reported side effect was transitory diarrhea (in 5%) after the start of PrEP. It is notable that the increased STI’s (syphilis, chlamydia and gonorrhea – 10%, 6% and 5%, respectively) – fact in accordance with global trends.
Conclusion: PrEP is an effective prevention of HIV infectionand deserves budgetary finance. The increase of STI’s requires concrete preventive implementations.

Keywords: HIV, PrEP, STI’s,

pdf - Download FULL TEXT /PDF 605 KB/
Please cite this article as: Pakov I, Birindzhieva E, Philipova I, Terzieva K, Gancheva G. Pre-Exposure Prophylaxis (PrEP) of HIV Infection – a Crucial Tool for Reducing the Burden upon the Public Health. J of IMAB. 2022 Oct-Dec;28(4):4688-4690. DOI: 10.5272/jimab.2022284.4688

Corresponding AutorCorrespondence to: Ivaylo Nikolaev Pakov, Clinic of Infectious Diseases, University Hospital Pleven, 8a, Georgi Kochev Str., Pleven 5800, Bulgaria; E-mail: ivaylo.pakov@gmail.com

1. Fact Sheet 2022. Global HIV statistics. UNAIDS. [Internet]
2. Samuel K. Getting to 95-95-95: global use of HIV generics would result in large reductions in spending, new infections and deaths. NAM AIDSmap. 9 July 2021. [Internet
3. Understanding Fast-Track: accelerating action to end the AIDS epidemic by 2030. UNAIDS. June2015. [Internet]
4. Girum T, Wasie A, Worku A. Trend of HIV/AIDS for the last 26 years and predicting achievement of the 90-90-90 HIV prevention targets by 2020 in Ethiopia: a time series analysis. BMC Infect Dis..PubMed]
5. 2020 Global AIDS update. Seizing the moment. Tackling entrenched inequalities to end epidemics. UNAIDS. 6 July 2020. [Internet]
6. Heath K, Levi J, Hill A. The Joint United Nations Programme on HIV/AIDS 95-95-95 targets: worldwide clinical and cost benefits of generic manufacture. AIDS. 2021 Dec 15;35(Suppl 2):S197-S203. [PubMed]
7. Davies O, Ustianowski A, Fox J. Pre-exposure Prophylaxis for HIV Prevention: Why, What, Who and How. Infect Dis Ther. 2016 Dec;5(4):407-416. [PubMed]
8. Guidance on Pre-exposure Oral Prophylaxis (PrEP) for Serodiscordant Couples, Men and Transgender Women Who Have Sex with Men at High Risk of HIV: Recommendations for Use in the Context of Demonstration Projects. WHO. Jul. 2012. [PubMed]
9. Global HIV & AIDS statistics - fact sheet. UNAIDS. 2021. [Internet]
10. Hillis A, Germain J, Hope V, McVeigh J, Van Hout MC. Pre-exposure Prophylaxis (PrEP) for HIV Prevention Among Men Who Have Sex with Men (MSM): A Scoping Review on PrEP Service Delivery and Programming. AIDS Behav. 2020 Nov;24(11):3056-3070.[PubMed]

Received: 31 August 2022
Published online: 18 November 2022

back to Online Journal